Jake, investors should be finding out within a couple months as to whether Cotara is tracked to be the new primary treatment for an $800 million per year market. What does that do to the intrinsic value of PPHM, independent of Bavi prospects?
My guess:
If PPHM achieves 20% of the market ($160 million per year) and a Price to Sales ratio of ten is applied, pps might stabilize at around $8. If Cotara dominates the market by capturing 60%, the pps might go to $24. Resultant funding being directed to Bavi trials ought to reap results within a couple years, so if Bavi is successful, a boost in valuation of another 5 to 10 fold is a prospect. That crosses the line to someone's $158.27 wish list valuation of a few year's back, LOL.
A series of events need to align to put PPHM on that track, but the prospect of that sort of success doesn't seem all that far fetched if Cotara and Bavi continue to perform as trials are indicating. Maybe the valuation dynamics of six years ago that brought pps to $16 for a day after a reporter erroneously overstated TCLN success will be back in play soon, this time backed by real data with positive results? Fun to think about while awaiting India results and new trial announcements.
Best wishes and IMO.
KT
News 
Market Data 
Discover 
